Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilars Reviews Could Be Extended Two Months In BsUFA II

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA hopes for first-cycle approvals by putting applications in a system like the 'Program' used for new drug reviews.

Advertisement

Related Content

What Goes Up … US FDA Expects 2016 NME Approval Total To Come Down
Complex ANDAs To Be Allowed Pre-Submission Product Meetings
Biosimilars Will Get PDUFA-Style Reviews Under New User Fee Plan
Biosimilar User Fee Agreement Offers FDA Funding Boost, Fee Structure Overhaul
Biosimilar User Fee Talks Begin With Industry Negotiating Amongst Itself
How To Get A Meeting With FDA: Guidance Describes Formal Meetings For Biosimilars
Buying Time: Industry Sacrifices Early To Gain Later With PDUFA V Review Model

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS079340

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel